GO:0051401 CH domain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051401 (CH domain binding) is a molecular function describing the selective binding of a protein to a calponin homology (CH) domain, a compact ~100-residue module found in signaling and cytoskeletal proteins.
• CH domains are best known as actin-binding modules, but they also mediate protein-protein interactions that control cytoskeletal organization, signal transduction and enzyme autoinhibition.
• The dystrophin actin-binding domain contains tandem CH domains whose internal dynamics govern actin engagement, making CH domain binding central to muscle membrane stability.
• MICAL proteins use CH-domain-containing regions for autoinhibition and for regulated actin disassembly, linking CH domain binding to redox-dependent cytoskeletal remodeling.
• CH domain binding is experimentally tractable by co-immunoprecipitation, isothermal titration calorimetry, NMR, X-ray crystallography and CRISPR-based perturbation of the interacting partners.
• Dysregulation of CH-domain-mediated interactions is implicated in muscular dystrophies, neurodevelopmental disorders and cancer cell migration, making this GO term a useful annotation target for disease models.
Description
GO:0051401, CH domain binding, is a molecular function term in the Gene Ontology that describes the ability of a protein or other molecule to bind selectively to a calponin homology (CH) domain. The CH domain is a roughly 100-amino-acid module that occurs in signaling and cytoskeletal proteins, where it typically forms a compact alpha-helical bundle that can engage actin filaments or partner proteins. Because CH domains are present in proteins such as dystrophin, alpha-actinin, spectrin and MICAL family oxidoreductases, the annotation GO:0051401 captures a broad but mechanistically coherent set of interactions that connect the cytoskeleton to signaling and membrane organization. For researchers, CH domain binding matters because it is a recurring node in mechanotransduction, cell polarity and membrane-cytoskeleton coupling. Mutations that alter CH-domain surfaces can change binding affinity, allosteric regulation or autoinhibition, and such changes have been linked to muscle disease and to altered actin dynamics in neurons. Annotating a protein with GO:0051401 therefore provides a compact, evidence-based statement about its interaction repertoire and helps prioritize it for structural and functional follow-up. This article summarizes the QuickGO definition of GO:0051401, explains the structural and mechanistic basis of CH domain binding, lists representative genes and proteins, and outlines CRISPR and biochemical methods that can be used to test whether a candidate interaction is causal in a given biological context.
CH domain binding At A Glance
| GO ID | GO:0051401 |
|---|---|
| GO term | CH domain binding |
| Ontology | molecular_function |
| Synonym | calponin homology domain binding |
| Definition | Binding to a calponin homology protein domain, a domain of 100 residues that occurs in signaling and cytoskeletal proteins. |
| Major function | Mediates selective protein-protein and protein-actin interactions through CH-domain-containing partners, contributing to cytoskeletal organization and signal transduction. |
| Domain size | Approximately 100 amino acid residues, typically folded as an alpha-helical bundle. |
| Representative CH-domain proteins | Dystrophin, alpha-actinin, spectrin, filamin, MICAL family proteins and related cytoskeletal/signaling factors. |
| Related GO aspects | Often co-annotated with actin binding, cytoskeletal anchoring and signal transduction processes. |
What Is GO:0051401?
In plain terms, GO:0051401 means binding to a calponin homology domain. The QuickGO definition states that this molecular function corresponds to binding to a CH domain, a domain of approximately 100 residues that occurs in signaling and cytoskeletal proteins. The synonym calponin homology domain binding is used interchangeably. The term is a molecular_function annotation and does not by itself specify a biological process or cellular location; those are captured by separate GO terms that often co-annotate with GO:0051401.
Why Is CH domain binding Important in Cell Biology?
CH domain binding is important because CH domains are among the most common actin- and cytoskeleton-associated modules in the human proteome, and the interactions they mediate sit at the interface between mechanical force, membrane organization and intracellular signaling. Small changes in CH-domain surface chemistry can shift binding equilibria, alter autoinhibition, or change how a protein partitions between actin filaments and signaling complexes, which is why GO:0051401 is a useful annotation for interpreting disease variants and for designing targeted perturbation experiments.
• CH domain binding underlies actin engagement by dystrophin, a key determinant of sarcolemmal stability in muscle.
• Tandem CH domains in dystrophin show internal dynamics that modulate actin-binding affinity, illustrating how CH domain binding can be allosterically tuned.
• MICAL proteins use CH-domain-containing architecture for autoinhibition and regulated actin disassembly, connecting CH domain binding to redox signaling.
• CH domain binding is relevant to cell migration and adhesion because many CH-domain proteins localize to focal adhesions and the cortical cytoskeleton.
• Disease variants that map to CH-domain surfaces can alter binding specificity, making GO:0051401 a useful lens for variant interpretation.
• CH domain binding provides a tractable target for biochemical reconstitution, since recombinant CH domains can be produced and tested in vitro.
• CRISPR knockout of CH-domain-containing proteins enables causal tests of whether a given interaction is required for a phenotype.
• The term supports cross-species annotation because CH domains are conserved from invertebrates to humans.
Molecular Mechanism of CH domain binding
Recognition of the CH domain fold
In simple terms: A binding partner recognizes the compact, helical shape of a CH domain.
CH domains are approximately 100-residue modules that fold into a compact alpha-helical bundle, and binding partners engage this fold through surface patches rather than through a single linear motif. Structural and biophysical studies of CH-domain-containing proteins such as dystrophin show that the domain presents a defined interaction surface whose dynamics can modulate partner engagement. In MICAL proteins, the CH-domain-containing region participates in autoinhibitory contacts that must be relieved for downstream activity, illustrating that CH domain binding can be intramolecular as well as intermolecular.
Actin engagement and cytoskeletal coupling
In simple terms: Many CH domains bind actin filaments, so CH domain binding often means anchoring a protein to the cytoskeleton.
The best-characterized function of CH domains is actin binding, and proteins such as dystrophin use tandem CH domains to associate with actin filaments at the membrane. The actin-binding domain of dystrophin is dynamic, and its internal motions influence how tightly the protein engages actin, which in turn affects sarcolemmal integrity. Because GO:0051401 describes binding to the CH domain itself, it captures the partner side of these interactions and complements actin-binding annotations on the CH-domain-containing protein.
Autoinhibition and allosteric control
In simple terms: Some proteins fold back on themselves so that a CH domain is blocked until a signal releases it.
MICAL proteins provide a clear example of CH-domain-linked autoinhibition, in which structural elements occlude or restrain catalytic and actin-remodeling activities until the protein is activated. The structural basis of MICAL autoinhibition shows how domain-domain contacts, including those involving CH-domain-containing regions, set the threshold for activation. This means that CH domain binding is not only a static interaction but can be a regulated switch that controls when a cytoskeletal or signaling output occurs.
Binding affinity, kinetics and cofactor effects
In simple terms: How strongly and how long a partner sticks to a CH domain depends on shape, charge and cellular conditions.
CH domain binding is governed by the same thermodynamic and kinetic principles as other protein-protein interactions, including buried surface area, electrostatic complementarity and conformational entropy. In dystrophin, the internal dynamics of the actin-binding domain influence binding behavior, showing that flexibility within the CH-domain region can tune affinity. Cellular conditions such as redox state and local ion concentrations can further modulate these interactions, as illustrated by redox-dependent regulation of MICAL activity.
Specificity and interaction networks
In simple terms: Different CH domains bind different partners, creating a network rather than a single switch.
CH domains are found in a wide range of signaling and cytoskeletal proteins, and the identity of the flanking sequences and adjacent domains determines which partners are engaged. This modularity allows CH domain binding to participate in larger interaction networks that link actin filaments to membranes, receptors and signaling enzymes. Annotating a protein with GO:0051401 therefore places it within this network and provides a starting point for mapping its functional partners.
Key Genes Involved in GO:0051401 CH domain binding
The following genes and proteins are representative of CH-domain-containing factors and their binding partners that are relevant to GO:0051401 annotation and experimental study.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DMD | Encodes dystrophin, which contains tandem CH domains that bind actin at the muscle membrane. | Central to muscular dystrophy research and to understanding CH-domain dynamics in actin binding. |
| MICAL1 | CH-domain-containing oxidoreductase involved in actin disassembly and autoinhibition. | Model for studying CH-domain-linked autoinhibition and redox-dependent cytoskeletal control. |
| MICAL2 | MICAL family member with CH-domain-containing architecture implicated in cytoskeletal remodeling. | Used to compare autoinhibitory mechanisms across MICAL paralogs. |
| ACTN1 | Alpha-actinin, a CH-domain-containing actin crosslinker. | Reference protein for CH-domain-mediated actin bundling. |
| ACTN2 | Muscle alpha-actinin with CH domains that organize sarcomeric actin. | Relevant to muscle disease models and CH-domain binding assays. |
| SPTAN1 | Alpha-II spectrin, a CH-domain-containing membrane skeleton protein. | Studied for membrane-cytoskeleton coupling and CH-domain interactions. |
| FLNA | Filamin A, an actin-crosslinking protein with CH domains. | Used to probe CH-domain-dependent cytoskeletal organization. |
| VCL | Vinculin, a focal adhesion protein that cooperates with CH-domain-containing partners. | Relevant to adhesion and migration studies involving CH domain binding. |
| TLN1 | Talin, a focal adhesion adaptor that interfaces with CH-domain-containing cytoskeletal proteins. | Used in mechanotransduction experiments linked to CH domain binding. |
| UTRN | Utrophin, a dystrophin-related protein with CH domains. | Compared with dystrophin in muscle and CH-domain binding studies. |
| PLEC | Plectin, a cytolinker that associates with actin and CH-domain-containing proteins. | Relevant to cytoskeletal crosslinking and CH-domain interaction mapping. |
| MYH9 | Non-muscle myosin heavy chain that functions in actomyosin networks with CH-domain proteins. | Used in contractility assays that depend on CH-domain-mediated anchoring. |
| ZAP | Zinc finger antiviral protein, a host restriction factor studied in complex with partner proteins. | Provides a broader example of domain-mediated antiviral complex assembly relevant to interaction studies. |
| PARP1 | Poly(ADP-ribose) polymerase that modulates ZAP antiviral activity. | Illustrates how post-translational modification can influence domain-mediated complexes. |
| ITGA1 | Integrin alpha-1, whose I domain shares structural features with CH-like modules. | Used in comparative studies of domain evolution and binding. |
| AF9 | YEATS-domain protein studied for CH-pi and amide-pi interactions in ligand binding. | Provides a chemical-biology reference for weak interaction contributions to domain binding. |
| SH2-domain proteins | Signaling proteins whose binding modes illustrate domain-specific interaction logic. | Used as a conceptual comparison for CH domain binding specificity. |
| PMA1 | Plasma membrane H+-ATPase with calcium-binding sites in its nucleotide-binding domain. | Example of ion-dependent regulation of domain function relevant to binding studies. |
How Is CH domain binding Regulated?
CH domain binding is regulated at several levels. Intramolecular autoinhibitory contacts can occlude CH-domain surfaces until a conformational change releases them, as shown for MICAL proteins. Post-translational modifications and redox conditions can further tune these interactions; for example, poly(ADP-ribose) potentiates ZAP antiviral activity, illustrating how modification of a partner can alter complex formation. In muscle, the internal dynamics of the dystrophin actin-binding domain provide a built-in regulatory mechanism that modulates actin engagement without requiring a separate factor. Together, these mechanisms mean that CH domain binding should be treated as a regulated interaction rather than a constitutive one.
CH domain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DMD | Duchenne and Becker muscular dystrophy; sarcolemmal instability | CRISPR knockout or point-mutation of CH-domain residues in myoblasts, followed by actin-binding assays |
| MICAL1 | Cytoskeletal remodeling and redox-sensitive actin disassembly | Knockout and autoinhibition-relieving mutations in neuronal or cancer cell lines |
| ACTN2 | Muscle cytoskeletal organization and sarcomeric disease | Knock-in of patient-like CH-domain variants in cardiomyocytes |
| SPTAN1 | Neurodevelopmental phenotypes linked to cortical cytoskeleton | Knockout and rescue with wild-type or mutant CH-domain constructs in neurons |
| ZAP | Antiviral restriction and complex assembly | Overexpression and knockout in infection models to test domain-dependent restriction |
Muscular dystrophy and sarcolemmal instability
Dystrophin contains tandem CH domains that mediate actin binding at the muscle membrane, and the dynamics of this actin-binding domain are directly relevant to sarcolemmal stability. Loss or alteration of dystrophin function causes Duchenne and Becker muscular dystrophies, and variants that perturb CH-domain-mediated actin engagement are expected to contribute to disease severity. Studying CH domain binding in this context helps explain how mechanical stress is transmitted across the membrane.
Neurodevelopmental and cytoskeletal disorders
CH-domain-containing proteins such as spectrin and alpha-actinin organize the cortical cytoskeleton in neurons, and disruption of these interactions can affect neuronal morphology and signaling. MICAL-family proteins add a redox-sensitive layer to actin regulation, and their autoinhibition is controlled by CH-domain-containing architecture. These features make CH domain binding relevant to neurodevelopmental phenotypes linked to cytoskeletal dysfunction.
Cancer cell migration and adhesion
Many CH-domain-containing proteins localize to focal adhesions and the cortical actin network, where they influence cell migration and invasion. Because CH domain binding helps anchor signaling proteins to actin, perturbations in these interactions can alter adhesion turnover and migratory capacity. This makes GO:0051401 a useful annotation when interpreting cancer cell motility phenotypes.
Host-pathogen interactions and antiviral restriction
Domain-mediated complex assembly is a general theme in antiviral restriction, as illustrated by the zinc finger antiviral protein and its regulation by poly(ADP-ribose). Although ZAP is not a canonical CH-domain protein, these studies provide a framework for how domain binding and post-translational modification cooperate to control antiviral complexes. Similar logic can be applied when studying CH-domain-containing host factors during infection.
From CH domain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a CH-domain-containing protein required for actin organization? | CRISPR knockout of the CH-domain gene in a relevant cell line, followed by actin imaging |
| Does a disease variant alter CH domain binding affinity? | Point-mutation knock-in of the variant, followed by co-immunoprecipitation or isothermal titration calorimetry |
| Can a tagged CH-domain protein be used to map interaction partners? | Tagged knock-in of an epitope or fluorescent tag at the endogenous locus |
| Does overexpression of a CH-domain protein change migration? | Overexpression in cancer cell lines with wound-healing and invasion assays |
| Is autoinhibition of a MICAL-family protein CH-domain dependent? | Knockout plus rescue with autoinhibition-relieving mutants |
| Does post-translational modification regulate CH-domain complex formation? | Knockout of modifying enzymes combined with interaction proteomics |
How to Study the CH domain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical association between a CH-domain protein and a partner | Validating candidate interactions from proteomics |
| Isothermal titration calorimetry | Binding affinity and stoichiometry | Comparing wild-type and mutant CH domains |
| Surface plasmon resonance | Association and dissociation kinetics | Screening partner fragments for CH-domain binding |
| X-ray crystallography | Atomic structure of a CH-domain complex | Defining the binding interface for MICAL-family proteins |
| NMR relaxation | Internal dynamics of a CH-domain region | Studying dystrophin actin-binding domain flexibility |
| Fluorescence microscopy | Cellular localization and cytoskeletal organization | Testing whether CH domain binding affects actin architecture |
| Affinity purification mass spectrometry | Interaction network of a CH-domain protein | Mapping partners for GO:0051401 annotation |
| CRISPR perturbation | Causal requirement for a CH-domain interaction | Knockout or knock-in followed by functional assays |
Biochemical binding assays
Recombinant CH domains and candidate partners can be tested by co-immunoprecipitation, pull-down assays, isothermal titration calorimetry and surface plasmon resonance to quantify affinity and specificity. These approaches are especially useful for comparing wild-type and mutant CH-domain surfaces identified in disease or structure-function studies.
Structural biology
X-ray crystallography and cryo-electron microscopy can resolve how a partner engages a CH domain, as demonstrated by structural studies of MICAL autoinhibition. NMR relaxation experiments are well suited to capturing the internal dynamics of CH-domain regions such as the dystrophin actin-binding domain.
Cell imaging and cytoskeletal readouts
Fluorescence microscopy of actin, focal adhesions and membrane markers can reveal whether perturbing CH domain binding changes cytoskeletal architecture or adhesion dynamics. Live-cell imaging of tagged CH-domain proteins provides a complementary view of their localization and turnover.
Interaction proteomics and bioinformatics
Affinity purification coupled to mass spectrometry can identify partners of CH-domain-containing proteins, and bioinformatics can map CH domains across proteomes to prioritize candidates for GO:0051401 annotation. Integrating these datasets with domain-family resources helps distinguish direct CH domain binding from indirect association.
How CRISPR Can Be Used to Study GO:0051401 CH domain binding
Knockout
CRISPR knockout of a CH-domain-containing gene removes the protein and allows researchers to test whether CH domain binding is required for a phenotype such as actin organization, adhesion or migration. Knockout lines are also useful for rescue experiments in which wild-type and binding-deficient CH-domain constructs are reintroduced.
Point Mutation
Point mutations that alter surface residues of a CH domain can be introduced to dissect which contacts are required for binding. Such mutants are valuable for separating actin-binding functions from partner-binding functions within the same domain.
Knock-in
Knock-in of epitope or fluorescent tags at the endogenous CH-domain locus enables interaction proteomics and live-cell imaging without overexpression artifacts. Disease-relevant CH-domain variants can also be knocked in to model their effects on binding and cytoskeletal function.
Overexpression
Overexpression of wild-type or mutant CH-domain proteins can reveal dominant effects on cytoskeletal organization and signaling. This approach is particularly useful for testing autoinhibition-relieving mutations in MICAL-family proteins.
How EDITGENE Supports CH domain binding Research
Researchers studying CH domain binding-related genes often need to determine whether a candidate gene is causally involved in a cytoskeletal or signaling phenotype, and CRISPR-based models provide a direct way to test that causality. By combining knockout, point-mutation, knock-in and overexpression strategies with interaction assays, it becomes possible to move from annotation to mechanism.
Contact EDITGENE today to design your custom CRISPR model for CH domain binding research.
Frequently Asked Questions About CH domain binding
What is GO:0051401?
GO:0051401 is the Gene Ontology molecular function term CH domain binding, defined as binding to a calponin homology protein domain, a domain of about 100 residues that occurs in signaling and cytoskeletal proteins.
What is a calponin homology domain?
A calponin homology (CH) domain is a compact, roughly 100-amino-acid module that typically folds into an alpha-helical bundle and is found in cytoskeletal and signaling proteins such as dystrophin and alpha-actinin.
What genes are involved in CH domain binding?
Representative genes include DMD, MICAL1, MICAL2, ACTN1, ACTN2, SPTAN1, FLNA, VCL, TLN1, UTRN and PLEC, all of which encode CH-domain-containing proteins or their partners.
How is CH domain binding studied experimentally?
Common approaches include co-immunoprecipitation, isothermal titration calorimetry, surface plasmon resonance, X-ray crystallography, NMR and CRISPR-based perturbation of the interacting partners.
Why is CH domain binding important in muscle?
Dystrophin uses tandem CH domains to bind actin at the muscle membrane, and the dynamics of this actin-binding domain are important for sarcolemmal stability.
Does CH domain binding regulate enzyme activity?
Yes, in MICAL proteins the CH-domain-containing architecture participates in autoinhibition, so CH domain binding can act as a regulatory switch for catalytic and actin-remodeling activity.
Can CRISPR be used to study CH domain binding?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models allow causal tests of whether a specific CH-domain interaction is required for a phenotype.
What diseases are linked to CH domain binding?
CH-domain-mediated interactions have been linked to muscular dystrophies, neurodevelopmental cytoskeletal disorders and cancer cell migration, among other conditions.
How do I annotate a protein with GO:0051401?
Annotation requires experimental evidence of binding to a CH domain, typically from biochemical, structural or interaction proteomics experiments, and should be supported by the primary literature.
What services does EDITGENE offer for CH domain binding research?
EDITGENE offers CRISPR knockout, point-mutation, knock-in, tagged knock-in, overexpression, library screening and bioinformatics services tailored to CH-domain-related research questions.
Conclusion
GO:0051401, CH domain binding, captures a mechanistically important molecular function that links actin-binding modules to signaling and cytoskeletal regulation. Understanding how partners engage CH domains, how autoinhibition controls these interactions, and how disease variants alter binding provides a framework for interpreting phenotypes in muscle, neurons and cancer cells. By combining structural, biochemical and CRISPR-based approaches, researchers can move from annotation to causal mechanism and identify which CH-domain interactions are worth targeting in a given biological context.
References
- 1. Horvath M et al.. 2024. Structural basis of MICAL autoinhibition.. Nat Commun 15(1):9810 PMID: 39532862
- 2. Fealey ME et al.. 2018. Dynamics of Dystrophin's Actin-Binding Domain.. Biophys J 115(3):445-454 PMID: 30007583
- 3. Bohn JA et al.. 2024. Functional anatomy of zinc finger antiviral protein complexes.. Nat Commun 15(1):10834 PMID: 39738020
- 4. Jaber Chehayeb R et al.. 2020. SH2 Domain Binding: Diverse FLVRs of Partnership.. Front Endocrinol (Lausanne) 11:575220 PMID: 33042028
- 5. Hollis JA et al.. 2025. Molecular exaptation by the integrin αI domain.. Sci Adv 11(37):eadx9567 PMID: 40929264
- 6. Gómez-Flores CL et al.. 2026. Identification of Calcium-Binding Sites in the Nucleotide Binding Domain of the Plasma Membrane H(+)-ATPase From Saccharomyces cerevisiae.. Chemphyschem 27(12):e202500713 PMID: 42324128
- 7. Krone MW et al.. 2020. More Than π-π-π Stacking: Contribution of Amide-π and CH-π Interactions to Crotonyllysine Binding by the AF9 YEATS Domain.. J Am Chem Soc 142(40):17048-17056 PMID: 32926780
- 8. Xue G et al.. 2022. Poly(ADP-ribose) potentiates ZAP antiviral activity.. PLoS Pathog 18(2):e1009202 PMID: 35130321
